Journal
OCULAR IMMUNOLOGY AND INFLAMMATION
Volume 26, Issue 3, Pages 477-484Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/09273948.2016.1236968
Keywords
Adalimumab; anti-TNF-; infliximab; non-infectious uveitis; refractory uveitis
Categories
Ask authors/readers for more resources
Purpose: To assess the efficacy of anti-TNF alpha (TNF-) therapy in patients with non-infectious uveitis.Methods: This was a monocentric observational study of 21 patients with non-infectious uveitis treated with anti-TNF-alpha. The primary endpoint was the control of ocular inflammation. The secondary endpoints included the study of macular thickness and visual acuity, changes in other treatments, and adverse effects.Results: The etiologies of uveitis were Behcet disease (33.3%), birdshot (14.3%), sarcoidosis (9.5%), and idiopathic uveitis (42.9%). Ocular inflammation was controlled at 3 months for 80.9% of patients, at 6 months for 94.7%, at 12 months for 83.3%, and at >12 months for 86.7%. Central macular thickness improved from 452 mu m at baseline to 307.5 mu m at 12 months (p = 0.002). Visual acuity also improved from 0.51(logMAR) before treatment to 0.24 at 12 months. The mean daily dose of prednisone decreased from 19.7 mg before treatment to 5.2 mg at 12 months (p<0.001). A total of 9.5% of patients experienced serious side-effects.Conclusions: Our study confirms the efficacy of anti-TNF for the control of short-term and long-term ocular inflammation, with high rates of complete clinical remission.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available